Hyogo, Japan – May 13, 2025 – JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”) has renewed its corporate philosophy and core values to mark the 50th anniversary of its founding and to set a clearer direction for the future.

JCR has long focused on rare and genetic diseases, earning recognition as a specialty pharmaceutical company built on scientific innovation. Through our work with protein, cell-based, and gene technologies, we’ve developed therapies and platforms that are expanding the possibilities of treatment. At the heart of it all is a simple promise—to improve people’s health through the medicines we create.

As we mark this milestone, we’ve taken a moment to reflect on what truly matters—our role in society, what we stand for, and how we move forward. This reflection has led us to renew our corporate philosophy, bringing even more clarity to our purpose and the values we share.

 

Our Corporate Philosophy

“We create treatments that go beyond rare disease to solve the world’s most complex healthcare challenges”

 

This renewed philosophy is built on two ideas we care deeply about – continuing to explore areas of medicine where no treatments yet exist, and expanding the reach of our innovations so they can support more patients, wherever they are.

JCR has long focused on these three values, and they have shaped the way we think and act— Reliability, Confidence, and Belief. As we move forward, we’ve taken a step back to reflect on what they mean today and how they will help guide us well into the future.

Our Core Values

1. Putting people first
Our community is our priority. Patients, families, physicians and our employees are at the heart of what we do.

2. Forging our own path
Unshackled from convention, we create new solutions that no-one else can.

3. Always advancing
We don’t stand still. Our research continuously pushes boundaries to deliver for patients and families.

4. Committed to excellence
We deliver the highest standards for partners, patients and employees.

With a renewed sense of purpose, each of us at JCR is moving forward—thinking boldly, acting with intention, and striving to close the gap in unmet medical needs. This is how we grow— together.

About JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients’ lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, HurlerScheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level.

Contact:
Investors & Media:
JCR Pharmaceuticals Co., Ltd.
Corporate Communications
ir-info@jp.jcrpharm.com